| Being positive despite illness: The contribution of positivity to the quality of life of cancer patients GV Caprara, V Castellani, G Alessandri, F Mazzuca, M La Torre, ... Psychology & health 31 (5), 524-534, 2016 | 52 | 2016 |
| Cancer patients submitted to innovative chemotherapeutic agents of intermediate emetogenic potential: antiemetic prescriptions and incidence of emesis Italian Group for Antiemetic Research, V De Angelis Tumori Journal 90 (1), 103-106, 2004 | 2 | 2004 |
| Genetic polymorphism can help physician choosing the best lung cancer chemotherapy S Lauro, S Angelini, CE Onesti, M Occhipinti, D Iacono, R Righini, R Giusti, ... Annals of Oncology 26, vi85, 2015 | 1 | 2015 |
| Electrochemotherapy treatment of cutaneous metastases from breast cancer P Mercantini, L Lorenzon, G Tarantino, G Balducci, M Ferri, F Mazzuca, ... The American Surgeon 81 (5), 222-225, 2015 | 1 | 2015 |
| Intradermal lymphoscintigraphy at rest and after a quick exercise in the functional assessment of the lymph drainage in patients with secondary lymphoedema. G Tartaglione, M Pagan, A Scoppola, C Capalbo, V Picone, CZ Di Rocco, ... EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 37, S458-S458, 2010 | 1 | 2010 |
| Immunohistochemical expression of Dicer in melanoma. C Capalbo, F Passarelli, Z di Rocco, A Scoppola, P Marchetti Journal of Clinical Oncology 28 (15_suppl), 8591-8591, 2010 | 1 | 2010 |
| Patients non-clinical related factors associated with the use of breast conservative surgery in the treatment of primary breast cancer in Italy G Porzio, A Matter, T Trapasso, C Ficorella, P Marchetti, AM Angelone, ... European Journal of Cancer 35, S159-S159, 1999 | 1 | 1999 |
| Three or Six Months of Adjuvant Chemotherapy for Colon Cancer: Compliance and Safety of the Phase III Italian Tosca Trial S Lonardi, R Labianca, G Rosati, M Di Bartolomeo, L Gianni, N Pella, ... Annals of Oncology 25, iv170, 2014 | | 2014 |
| Worse prognosis of KRAS C.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with first-line triplet chemotherapy plus bevacizumab (FIr-B/FOx … G Bruera, K Cannita, D Di Giacomo, A Lamy, AV Giordano, R Vicentini, ... Journal of Clinical Oncology 31 (15_suppl), e14596-e14596, 2013 | | 2013 |
| con il patrocinio dell’Associazione Italiana di Oncologia Medica A Corsini, P Pronzato, V Adamo, A Ardizzoni, S Barni, S Bracarda, ... | | 2013 |
| 1432 POSTER Pharmacogenetic Assessment of Toxicity After Docetaxel Chemotherapy in Breast Cancer I Russo, MC Di Trapani, G Gentile, V Sgroi, A Roselli, L Trasatti, ... European Journal of Cancer, S179, 2011 | | 2011 |
| RISK FACTORS, CLINICAL FEATURES AND OUTCOME OF EARLY ONSET PANCREATIC CANCER M Piciucchi, G Capurso, R Valente, M Cavallini, A Romiti, V Barucca, ... Digestive and Liver Disease 42, S82-S82, 2010 | | 2010 |
| PRELIMINARY DATA OF INCREASED RATE OF POTENTIALLY CURATIVE RESECTION OF LIVER METASTASES AFTER INTENSIVE CHEMOTHERAPY IN METASTATIC COLO-RECTAL CANCER PATIENTS A Santomaggio, K Cannita, LP Baldi, G Porzio, M Mancini, M Tudini, ... ANNALS OF ONCOLOGY 20, 2009 | | 2009 |
| P2. 106. IMRT with simultaneous integrated boost in head and neck carcinomas–A preliminary analysis S Ghoshal, S Chakraborty, A Sankar Oral Oncology Supplement 1 (3), 195, 2009 | | 2009 |
| PCN138 INFORMATION NEEDS: A STUDY ABOUT ONCOLOGICAL PATIENTS IN THE ITALIAN CONTEXT S Passalacqua, A Mozzetta, C Di Pietro, P Marchetti, S Tabolli Value in Health 7 (12), A283, 2009 | | 2009 |
| LCK-POSITIVE TUMOR-INFILTRATING LYMPHOCYTES CONFER A FAVOURABLE CLINICAL OUTCOME IN PATIENTS WITH STAGE I NON-SMALL-CELL LUNG CANCER G Natoli, S Scarpino, A Pasanen, E Duranti, C Pompili, E Rendina, ... ANNALS OF ONCOLOGY 19, 113-113, 2008 | | 2008 |
| The impact of searching for BRCA1/2 large genomic rearrangement on BRCAPRO carrier prediction C Capalbo, A Buffone, AR Vestri, E Ricevuto, T Sidoni, L Ottini, M Falchetti, ... ANNALS OF ONCOLOGY 18 (11), 84-84, 2007 | | 2007 |
| A multicenter phase II study of epirubicin with low-dose trastuzumab as a first line treatment in Her-2 overexpressing metastatic breast cancer: preliminary results M Zilli, D Tursi, C Carella, E Ricevuto, P Marchetti, A Gennari, C Orlandini, ... EJC Supplements 2 (4), 165, 2006 | | 2006 |
| Weekly administration of paclitaxel: peculiarity and biological premises P Marchetti, G Ronzino, E Ricevuto, G Porzio, C Ficorella Tumori 87, 1-7, 2001 | | 2001 |
| Phase II study of docetaxel (D) and ifosfamide (I) in advanced non-small cell lung cancer (NSCLC).(TAXIT-209). M Rinaldi, A Contu, P Marchetti, M Della Giulia, P Foggi, G Del Monte, ... ANNALS OF ONCOLOGY 11, 113-113, 2000 | | 2000 |
